Roche Holding Ltd · SIX:RO
Roche — FY 2025 Earnings Presentation
78 slides from Roche's earnings presentation, Jan 29, 2026
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2025 results
Roche 2025 results Basel, 29 January 2026
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: FY 2025 performance, next innovation cycle, Outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 6: 2025: Strong financial and pipeline performance
2025: Strong financial and pipeline performance FY results at CER ▪ Group sales growth +7%, +9% for Pharma and +2% for Diagnostics (despite China healthcare pricing reforms) ▪ Strong operating performance with Core OP +13% and Core OP margin +1.9%p; Core EPS +11% ▪ Full year LOE impact was CHF -0.7b
Slide 7: 2025: Consistent strong growth
2025: Consistent strong growth Diagnostics impacted by healthcare pricing reforms in China in 2025 Group sales growth %CER +15% +10% +9% +9% +9% +9% +8% +8% +6% +6% +5% +2% +1% +2% +1% 0% COVID-19 pandemic Pandemic phase out Post-pandemic Base business: +1%* Base business: +8%* Business growth: +8%*
Slide 8: 2025: Continued strong Pharma sales driving Group growth
2025: Continued strong Pharma sales driving Group growth Diagnostics excluding China grew +7% at CER FY 2025 FY 2024 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 47.7 46.2 3 9 Diagnostics Division 13.8 14.3 -3 2 Roche Group 61.5 60.5 2 7 CER: Constant exchange rates (avg. full year 2024)
Slide 9: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio All therapeutic areas delivering strong growth Diagnostics: Molecular Lab and 2025 sales Pathology Lab with strong growth; Core Lab impacted by China healthcare +2% (CHFbn, YoY CER growth) Phesgo: Global conversion rates >50%*; HER2+ BC pricing reforms; excl
Slide 10: Achieved 2025 upgraded guidance
Achieved 2025 upgraded guidance LOE impact of -0.7bn Guidance Results Group sales growth1 Mid single digit sales growth +7% High single digit to low double digit Core Core EPS growth1 +11% EPS growth (from high single digit growth) Dividend outlook Further increase dividend in Swiss francs2 CHF 9.80
Slide 11: Substantial 2025 pipeline progress across all TAs
Substantial 2025 pipeline progress across all TAs 12 positive Phase III readouts unlocking significant upside potential Positive key Phase III readouts 10 NMEs new to Phase III ▪ lidERA in adjuvant ER+ BC NXT007 zosurabalpin giredestrant in hemophilia A in bacterial infections ▪ evERA in 2L+ ER+ mBC
Slide 12: Agreement with the US Government reached
Agreement with the US Government reached Roche portfolio exempt from tariffs and demo projects (GUARD and GLOBE) Implications of the agreement USD 50bn investment in manufacturing, infrastructure, R&D Medicaid rebates 13+1* manufacturing and 15+1* R&D sites in the US 1 Genentech to offer states addi
Slide 13: FY 2025 performance, next innovation cycle, Outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 14: Substantial progress made across key initiatives
Substantial progress made across key initiatives R&D Excellence efforts have already translated into a material shift of the portfolio value Key initiatives Key milestones achieved R&D Excellence progress 2020 2022 2023 2024 2025 Introduction of the Bar Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 >60% of
Slide 15: Strong on-market portfolio with no patent cliff ahead
Strong on-market portfolio with no patent cliff ahead Significant upside potential being unlocked in 2025/26; key Ph III readouts 2027 onwards Today’s on-market Pharma portfolio Positive key Ph III readouts in 2025 Next key NMEs expected to to deliver growth until 2028 enabling filings, including 3
Slide 16: Substantial progress on pipeline rejuvenation
Substantial progress on pipeline rejuvenation Prioritization of high-impact projects and strategic business development Portfolio evolution (NME additions / removals) Portfolio value Average peak sales per 8 -8 pipeline project, CHF bn1 81 4 -3 1 FGF21 analog -5 3 -4 in MASH 3 +60% -9 5 -5 3 -2 1 -5
Slide 17: Roche Diagnostics: Key technology launches driving future growth
Roche Diagnostics: Key technology launches driving future growth CGM, Mass Spec and SBX each represent >1bn CHF opportunities Accu-Chek® SmartGuide cobas® i601 Mass Spec AXELIOS (SBX) (2024) (2024) (2026) ▪ 14-day real-time glucose sensor with ▪ First fully integrated IVD platform ▪ World record for
Slide 18: FY 2025 performance, next innovation cycle, Outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 19: Sustaining pipeline momentum through 2026
Sustaining pipeline momentum through 2026 10 key Ph III readouts; significant progress in obesity portfolio expected Key regulatory milestones Key Phase III readouts Phase II readouts in obesity giredestrant filing giredestrant in 1L ER+/HER2- mBC CT-388 (Ph III to be initiated) in adjuvant ER+/HER2
Slide 20: Future growth outlook: Up to 19 NMEs with launch potential by 2030
Future growth outlook: Up to 19 NMEs with launch potential by 2030 First post Bar NMEs expected to readout in 2027; peak sales assumptions for fenebrutinib and sefaxersen raised 0.5-1bn peak sales 1-2bn peak sales afimkibart 2-3bn peak sales >3bn peak sales CT-388 IBD, AtD, RA, MASH Obesity +/- T2D
Slide 21: 2026 guidance
2026 guidance LOE impact of roughly CHF 1bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Loss of exclusi
Slide 22: Finance
Finance Alan Hippe Chief Financial Officer
Slide 23: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 24: 2025: Group performance
2025: Group performance Sales increase of +7% and Core EPS increase of +11% 2025 2024 Change in % CHFm CHFm CHF CER Sales 61,516 60,495 +2 +7 Core operating profit 21,833 20,823 +5 +13 as % of sales 35.5 34.4 Core net income 16,575 16,011 +4 +11 as % of sales 26.9 26.5 Core EPS (in CHF) 19.46 18.80
Slide 25: 2025: Group sales growth at +7%
2025: Group sales growth at +7% Continued strong Pharma sales driving Group growth +7% at CER CHFm +871 +4,792 -745 -579 -3,318 60,495 61,516 FY 2024 Pharma LOE Dia China Fx FY 2025 (excl. LOE) (excl. China) healthcare pricing reforms CER: Constant exchange rates (avg. full year 2024); LOE: Loss of
Slide 26: 2025: Group Core operating profit
2025: Group Core operating profit Core operating profit higher by +13%, driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 61,516 +4,339 7% Other revenue 1,840 +15 1% Cost of sales -15,864 -1,136 7% R&D -12,243 +332 -3% SG&A -13,838 -649 5% OOI&E
Slide 27: 2025: Core operating profit and margin
2025: Core operating profit and margin % of sales 47.7% 49.2% 35.5% +1.9%p¹ 34.4% +1.9%p¹ +13%¹ 16.8% 14.4% CHFm +13%¹ 23,440 21,833 22,014 -1.1%p¹ 20,823 -4%¹ 2024 2025 2,402 1,998 Roche Group Pharma Division Diagnostics Division Note: Group Core operating profit includes -3.6bn from Corporate (-3.
Slide 28: 2025: Core net financial result
2025: Core net financial result Improvement mainly driven by lower losses from foreign exchange results (Other) CHFm ▪ Net financial result worsened by -60m / +5% at CER ▪ Interest expenses1 improved by +10m / -1% at CER -1,477 -1,610 +69 +199 -88 -47 FY 2024 Equity Net interest Interest Other FY 20
Slide 29: 2025: Core tax rate
2025: Core tax rate Higher tax rate mainly due to changes in profit mix and lower impact from resolution of tax disputes +1.9%p -0.9%p 18.6% +1.4%p -1.4%p 16.7% 19.5% 18.1% Effective Resolution of Effective tax Profit mix Effective tax Resolution of Effective tax rate tax disputes rate FY 2024 and o
Slide 30: 2025: Core EPS
2025: Core EPS Increase in operations partially offset by a higher tax rate and lower gains on product disposals +11.0% -1.2%p -0.3%p -2.8%p 21.45 +15.8%p -0.5%p 19.33 FY 2024 Operations1 Product disposals Financial Effective tax All other effects FY 2025 & disposal of income/expense rate change sub
Slide 31: 2025: Non-core and IFRS income
2025: Non-core and IFRS income Non-core items lower vs. PY due to lower impairment of goodwill 2025 2024 Var. at Change in % CHFm CHFm CERm CHF CER Core operating profit 21,833 20,823 +2,714 +5 +13 Global restructuring plans -2,164 -1,891 -344 Amortisation of intangible assets -669 -736 +44 1 Impair
Slide 32: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 33: 2025: Group operating free cash flow
2025: Group operating free cash flow OFCF down by -12% driven by NWC movement (higher year end receivables) and investments in IA (Zealand Pharma) CHFm +1,429 -2,863 -420 -645 -1,547 20,209 OFCF down by -12%/ -2,499m at CER 17,710 16,163 FY 2024 OP, net of cash NWC Investments Investments FY 2025 Fo
Slide 34: 2025: Operating free cash flow and margin
2025: Operating free cash flow and margin % of sales 48.3% 47.7% 49.2% 41.0% 33.3% 26.3% 35.5% +1.9%p¹ -6.8%p¹ 34.4% -6.1%p¹ 12.1% +1.9%p¹ 4.9% +13%¹ 16.8% 14.4% CHFm +13%¹ -5.9%p¹ 23,440 21,833 22,288 22,014 -6%¹ -1.1%p¹ 20,823 20,121 19,539 -12%¹ 16,163 -48%¹ -4%¹ 1,734 2024 2024 2025 2025 2,402 6
Slide 35: 2025: Group net debt development
2025: Group net debt development Net debt lower by CHF 1.2bn vs. YE 2024 Free cash flow CHF +11.8 CHFbn Dividends paid -8.4 -4.4 Trans. own eq. inst. -1.0 M&A & all. trans. -3.1 Curr. transl. & oth. +1.8 Taxes -3.1 Treasury -1.2 -17.3 +16.2 -16.2 -10.7 Net debt Operating Non-operating Dividends, M&A
Slide 36: Balance sheet 31 December 2025
Balance sheet 31 December 2025 Equity ratio at 38% (31 Dec 2024: 36%) % change in CER % change in CER CHFbn vs. 31 Dec 2024 vs. 31 Dec 2024 Cash and 101.8 100.7 +7% 101.8 100.7 +7% marketable 17.3 15.5 -5% securities 17% Current 27.0 28.0 15% Other 27% 28% +12% liabilities current 22.7 23.3 23% +11%
Slide 37: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 38: 2025: Currency impact and outlook
2025: Currency impact and outlook USD / CHF In 2025 impact1 is (%p): +3% -3% -4% -6% Q1 Q2 Q3 Q4 0.90 0.89 0.88 0.88 Sales +1 -8 -7 -7 0.87 0.86 0.84 0.83 Q1 HY YTD FY Sep 0.91 0.90 0.88 0.84 0.83 0.82 0.80 0.81 0.80 0.80 0.80 0.80 Sales +1 -3 -5 -5 Monthly avg fx rates 2025 Average YTD 2025 Average
Slide 39: 2025: Core EPS
2025: Core EPS Core EPS 2025 of CHF 19.83 is basis for Core EPS outlook 2026 at CER CHF 19.83 19.46 +0.37 Core EPS 2025 2025 foreign Core EPS 2025 basis as reported exchange losses: for outlook core EPS Core EPS impact growth 2026 at CER CER: Constant exchange rates (avg. full year 2025); EPS: Earni
Slide 40: 2026 guidance
2026 guidance LOE impact of roughly CHF 1bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Loss of exclusi
Slide 41: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 42: Prospective change in income statement presentation 2026
Prospective change in income statement presentation 2026 Further centralization of functions with global accountability: Legal costs to be reported as SG&A Corporate Changes in Income Statement presentation ▪ Implementation effective 1 January 2026: Most legal costs reported as SG&A under Corporate
Slide 43: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 44: Roche Pharma: Key priorities
Roche Pharma: Key priorities Sustain momentum through commercial excellence, key launches and portfolio rejuvenation Maximize on-market portfolio Deliver key launches Progress post Bar NMEs Current on-market portfolio to deliver Upcoming launches to support Prepare entry into broad scale DAs, growth
Slide 45: 2025: Pharmaceuticals sales
2025: Pharmaceuticals sales Continued strong growth across all regions FY 2025 FY 2024 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 47,669 46,171 3 9 United States 25,355 24,774 2 8 Europe 9,164 8,832 4 5 Japan 2,882 2,874 0 5 International 10,268 9,691 6 ##### 14 CER: Constant exchange ra
Slide 46: 2025: Pharmaceuticals Core operating profit
2025: Pharmaceuticals Core operating profit Core operating profit outgrowing sales with +13%, driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 47,669 +4,047 9% Other revenue 1,782 -14 -1% Cost of sales -8,678 -624 7% R&D -10,399 +293 -3% SG&A -7
Slide 47: 2025: Diversified set of key growth drivers
2025: Diversified set of key growth drivers Phesgo, Xolair, Ocrevus, Hemlibra, Vabysmo, and Polivy driving growth Phesgo 48% Xolair 32% Ocrevus 9% Hemlibra 11% Vabysmo 12% Polivy 38% Xofluza 184% Evrysdi 13% Elevidys 84% Columvi 75% Gazyva 14% Itovebi >500% Tecentriq 3% Alecensa 6% Enspryng 23% Luns
Slide 48: Oncology growing +2% driven by the HER2+ franchise
Oncology/Hematology Oncology growing +2% driven by the HER2+ franchise Giredestrant: evERA US filing achieved and positive Ph III (lidERA) in adj. ER+/HER2- BC presented at SABCS Q4 update Itovebi Avastin CHF 113m / +* ▪ Phesgo: Global conversion rate climbing to 54%** CHF 973m / -17% Others ▪ Perje
Slide 49: Giredestrant: Positive Ph III (lidERA) results in adjuvant ER+/HER2- BC
Oncology/Hematology Giredestrant: Positive Ph III (lidERA) results in adjuvant ER+/HER2- BC First and only oral SERD to show superior iDFS in the adjuvant setting Ph III (lidERA) iDFS results in adjuvant ER+/HER2- BC1 100 Giredestrant SOC ET n = 2084 n = 2086 80 100 97.7% 94.6% Events, n (%) 140 (6.
Slide 50: Giredestrant: Next-gen SERD with potential to replace SOC ET in ER+ BC
Oncology/Hematology Giredestrant: Next-gen SERD with potential to replace SOC ET in ER+ BC Complemented by a portfolio of potentially BIC molecules allowing combinations Potential to redefine treatment paradigm in ER+ BC Differentiated molecules targeting key signaling nodes Low risk Medium risk Hig
Slide 51: Polivy US patient share in 1L DLBCL reaching 36%
Oncology/Hematology Polivy US patient share in 1L DLBCL (IPI 0-5) reaching 36% Lunsumio SC in 3L+ FL achieved US and EU approval Q4 update Columvi Lunsumio CHF 288m / +75% CHF 114m / +68% ▪ Hemlibra: Continued global growth; increasing adoption in non- PiaSky inhibitor patients MabThera/Rituxan CHF
Slide 52: Ocrevus: >50% of global growth in Q4 driven by SC
Neurology Ocrevus: >50% of global growth in Q4 driven by SC First positive Ph III results for fenebrutinib in RMS (FENhance 2) and PPMS (FENtrepid) Q4 update Elevidys Others ▪ Ocrevus: >17,500 patients on Ocrevus SC globally CHF 341m / +84% CHF 362m / -3% ▪ US: >60% of SC volume coming from communit
Slide 53: Fenebrutinib: Potential for FIC and BIC in both RMS and PPMS
Neurology Fenebrutinib: Potential for FIC and BIC in both RMS and PPMS First and only BTKi with positive results in Ph III trials in RMS (FENhance 2) and PPMS (FENtrepid) Designed to control relapsing and progressive biology Optimized PK profile1 Free plasma concentration of BTKis fenebrutinib BTKi
Slide 54: Xolair strong growth momentum driven by food allergy
Immunology Xolair strong growth momentum driven by food allergy Gazyva: Positive Ph III results in SLE (ALLEGORY) and INS (INShore); EU approval for LN achieved Q4 update ▪ Xolair: Strong food allergy launch with >100k patients treated Others CHF 898m / -1% Actemra ▪ Biosimilar launch expected H2 20
Slide 55: Vabysmo continued strong global growth
Ophthalmology Vabysmo continued strong global growth Vamikibart in UME and Enspryng in TED to be filed in 2026 Q4 update Luxturna CHF 41m / +146% Susvimo ▪ Vabysmo: Continued market share gains across early launch Lucentis CHF 9m / +132% countries and ongoing global expansion CHF 58m / -58% ▪ US bra
Slide 56: CVRM pipeline: Ph III enabling data for five NMEs expected in 2026
Cardiovascular, Renal & Metabolism CVRM pipeline: Ph III enabling data for five NMEs expected in 2026 Positive Ph II (103) for CT-388 in obesity w/o T2D: Placebo-adjusted WL of 22.5% at 48w (efficacy estimand) achieved Clinical development Q4 update ▪ CT-388 in obesity without T2D: Positive Ph II (1
Slide 57: 2026: Key newsflow outlook
2026: Key newsflow outlook* Giredestrant + everolimus (post CDKi ER+/HER2- mBC) filed in US Compound Indication Milestone giredestrant adjuvant ER+/HER2- early BC US/EU filing giredestrant + everolimus post CDKi ER+/HER2- mBC EU filing/US approval Gazyva SLE US/EU filing Gazyva INS US/EU filing Ensp
Slide 58: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 59: 2025: Diagnostics sales
2025: Diagnostics sales Diagnostics growing at +2%, impacted by China healthcare pricing reforms CER: Constant exchange rates (avg. full year 2024) 59
Slide 60: 2025: Diagnostics highlights
2025: Diagnostics highlights Diagnostics growing at +2%, impacted by China healthcare pricing reforms CHFbn YoY CER growth ▪ Immunodiagnostics (-3%) Core Lab 0% ▪ Clinical chemistry (+7%) ▪ Blood screening (+3%) Molecular Lab +4% ▪ Infectious diseases (+1%) Near Patient ▪ BGM (-2%) -3% Care ▪ Liat P
Slide 61: 2025: Diagnostics regional sales
2025: Diagnostics regional sales Strong growth in Latin America, North America, and EMEA North America +9% EMEA ~32% of divisional sales +6% ~36% of divisional sales Asia Pacific Latin America -12% +11% ~24% of divisional sales ~8% of divisional sales Growth rates at constant exchange rates (avg. fu
Slide 62: 2025: Diagnostics Core operating profit
2025: Diagnostics Core operating profit Core operating profit lower by -4% driven by China healthcare pricing reforms 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 13,847 +292 2% Other revenue 58 +30 100% Cost of sales -7,186 -512 7% R&D -1,844 +39 -2% SG&A -2,923 +73 -2% OOI&E 46 -23 -32% Core
Slide 63: cobas i 601 Mass Spectrometry wave 1 menu CE mark
cobas® i 601 Mass Spectrometry wave 1 menu CE mark Mass spec assay menu expansion to cover the vast majority of routine testing demand cobas® i 601 Mass Spectrometry wave 1 menu Market needs and opportunity ▪ Market Opportunity: The current clinical mass spectrometry market is CHF 3bn, composed of l
Slide 64: Elecsys Dengue Ag CE mark
Elecsys® Dengue Ag CE mark Highly reliable automated serology assay for the detection of acute dengue infection Elecsys® Dengue Ag test Market needs and opportunity ▪ High Burden: Dengue is the most common mosquito-borne viral disease globally with an estimated 390m infections annually1 ▪ Difficult
Slide 65: cobas BV/CV CE mark
cobas® BV/CV CE mark Important molecular menu gap fill to expand in the fast-growing molecular STI segment Expanding STI menu Market opportunity ▪ The sexual health diagnostics market is valued at CHF 1.1bn with a yearly growth rate of 11%1 ▪ Vaginitis is the primary growth driver in the STI segment
Slide 66: cobas liat Bordetella panel CE mark and FDA clearance
cobas® liat Bordetella panel CE mark and FDA clearance Rapid and accurate detection of Bordetella to enable early intervention and reduce potential complications cobas® liat assay menu Market needs and opportunity ▪ High Burden: Pertussis causes 24.1 million cases annually, resulting cobas® liat Bor
Slide 67: Diagnostics key launches 2026
Diagnostics key launches 2026 Area Product Description Market Status Molecular Novel high-throughput solution for ultra-rapid, scalable, and flexible sequencing powered by Sequencing by Systems Lab AXELIOS Sequencing Solution Expansion (SBX) technology Global Non-invasive blood-based biomarker to en
Slide 68: Invitation to Diagnostics Day 2026
Invitation to Diagnostics Day 2026 Roche Diagnostics Day: 12 May London / hybrid event 14:00 - 16:45 CEST / 13:00 - 15:45 BST 08:00 - 10:45 am EDT / 05:00 - 07:45 am PDT 68
Slide 69: Doing now what patients need next
Doing now what patients need next
Slide 70: Roche Group development pipeline
Roche Group development pipeline
Slide 71: Changes to the development pipeline
Changes to the development pipeline Q4 2025 update New to phase I New to phase II New to phase III New to registration 5 NMEs: 1 AI: 1 NME: 1 NME (US): RG6913 NME – DME RG6631 afimkibart (anti-TL1A) - rheumatoid RG7935 prasinezumab - Parkinson’s RG6171 giredestrant + everolimus - RG6496 HTT SNP ASO
Slide 72: Roche Group development pipeline
Roche Group development pipeline Phase I (40 NMEs + 6 AIs) Phase II (15 NMEs + 7 AIs) RG6026 Columvi monotherapy + combos heme tumors RG6382 CD19 x CD3 SLE RG6171 giredestrant endometrial cancer RG6076 englumafusp alfa combos heme tumors RG6377 Anti-leukocyte trafficking antibody IBD RG6180 autogene
Slide 73: Roche Group development pipeline
Roche Group development pipeline Phase III (10 NMEs + 27 AIs) Registration US & EU (1 NME + 1AI) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD RG6171 giredestrant + everolimus+ post-CDK4/6 ER+/HER2- BC RG6013 Hemlibra Type 3 VWD RG62992 sefaxersen (ASO factor B) IgA nephropathy RG7
Slide 74: Expected regulatory submissions
autogene cevumeran RG6180 Expected regulatory submissions* solid tumors divarasib + New Molecular Entities: Lead and additional indications RG6330 pembrolizumab 1L NSCLC NXT007 prasinezumab RG6512 RG7935 hemophilia Parkinson’s New Molecular Entity (NME) Cardiovascular, Renal & Metabolism flizasertib
Slide 75: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications PiaSky New Molecular Entity (NME) Cardiovascular, Renal & Metabolism RG6107 Additional Indication (AI) Neurology aHUS Oncology / Hematology Ophthalmology Immunology Other Itovebi + fulvestrant RG6114 post CDKi HR+ PIK3CA-mut.
Slide 76: Major pending approvals 2025
Major pending approvals 2025 US EU China Japan-Chugai giredestrant + everolimus Susvimo Polivy + chemo Lunsumio + Polivy RG6171 post-CDK4/6 ER+/HER2- BC RG6321 wAMD RG7596 r/r DLBCL RG7828 2L+ DLBCL Filed Dec 2025* Filed July 2025 Filed May 2025 Filed May 2025 Tecentriq Alecensa RG7446 ctDNA+ high-r
Slide 77: Major granted approvals 2025
Major granted approvals 2025 US EU China Japan-Chugai TNKase Columvi + chemo Lunsumio Tecentriq RG3625 stroke RG6026 2L DLBCL RG7828 3L+ FL RG7446 Alveolar Soft Part Sarcoma Feb 2025 April 2025 Dec 2024 Feb 2025 Susvimo Xofluza Itovebi + palbociclib + fulvestrant Elevidys RG6321 DME RG6152 influenza
Slide 78: Doing now what patients need next
Doing now what patients need next